Key points are not available for this paper at this time.
In October 2022, our multicentered institution shifted from using alteplase to tenecteplase for the thrombolytic treatment of acute ischemic stroke (AIS). We aim to report and compare the incidence of hemorrhagic transformation and symptomatic intracranial hemorrhage (sICH) in patients treated with alteplase and tenecteplase at our institution.
Caicedo et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: